Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia.

Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia. Haematologica. 2020 Sep 28;Online ahead of print: Authors: Wei H, Zhou C, Lin D, Liu B, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Chen J, Zhang J, Jin J, Qiu S, Gu R, Wang Y, Mi Y, Wang J PMID: 33054134 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33054134?dopt=Abstract

Source: Haematologica - September 28, 2020 Category: Hematology Authors: Wei H, Zhou C, Lin D, Liu B, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Chen J, Zhang J, Jin J, Qiu S, Gu R, Wang Y, Mi Y, Wang J Tags: Haematologica Source Type: research

More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia